AN2 Therapeutics Inc Cash Flow Conversion Efficiency
AN2 Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has a cash flow conversion efficiency ratio of -0.092x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.00 Million) by net assets ($75.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AN2 Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of AN2 Therapeutics Inc from 2019 to 2025. This chart illustrates how AN2 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AN2 Therapeutics Inc stock price for real-time trading data and today's change.
AN2 Therapeutics Inc Cash Flow Conversion Ratio Explained
AN2 Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AN2 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AN2 Therapeutics Inc ranked by their cash flow conversion efficiency. Also see ANTX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ram Essential Services Property Fund
AU:REP
|
0.018x |
|
Adagene Inc
NASDAQ:ADAG
|
-0.139x |
|
Mountain & I Acquisition Co Corp
NASDAQ:MCAA
|
-0.001x |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
-0.212x |
|
Compugen
TA:CGEN
|
0.049x |
|
Vivozon Healthcare Inc
KQ:082800
|
-0.011x |
|
Sutro Biopharma
NASDAQ:STRO
|
0.371x |
|
Agora S.A.
WAR:AGO
|
0.079x |
Annual Cash Flow Conversion Efficiency for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of AN2 Therapeutics Inc from 2019 to 2025. Review AN2 Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.06 Million | $-29.83 Million | -0.562x | +6.57% |
| 2024-12-31 | $81.85 Million | $-49.26 Million | -0.602x | -40.83% |
| 2023-12-31 | $124.70 Million | $-53.29 Million | -0.427x | -21.79% |
| 2022-12-31 | $95.37 Million | $-33.46 Million | -0.351x | -6.04% |
| 2021-12-31 | $61.91 Million | $-20.48 Million | -0.331x | +83.03% |
| 2020-12-31 | $2.75 Million | $-5.36 Million | -1.950x | -277.50% |
| 2019-12-31 | $4.81 Million | $-2.49 Million | -0.517x | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more